Richard A Miller Md bought $1000k of CRVS
President and CEO at Corvus Pharmaceuticals, Inc.. 577,634 shares at an average of $1.73, traded May 6, 2024, filed May 7, 2024.
Score components
- +25RoleCEO
- +25Trade size$1000k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context51% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +25.0%, 3m +78.6%, 6m +449.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-24-000231, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 6, 2024 | POpen-market purchase Common Stock | +577,634 | $1.73 | $1000k | 577,634 | May 7, 2024 |
| May 6, 2024 | POpen-market purchase Warrant (Right to Buy)derivative | +559,073 | - | - | 559,073 | May 7, 2024 |
Related signals
Other insiders at Corvus Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | CRVSbuy Corvus Pharmaceuticals, Inc. | David Scott Moore director | $250k 21,700 shares | - | |
| 37Weak | CRVSbuy Corvus Pharmaceuticals, Inc. | Richard A Miller Md President and CEO | $83k 6,932 shares | +1% | |
| 53Moderate | Corvus Pharmaceuticals, Inc. | Peter A. Thompson director, owner | $4.9M 1,176,332 shares | -14% | |
| 53Moderate | Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | $4.9M 1,176,332 shares | -14% | |
| 40Moderate | Corvus Pharmaceuticals, Inc. | William Benton Jones See Remarks | $35k 20,000 shares | +15% | |
| 41Moderate | Corvus Pharmaceuticals, Inc. | William Benton Jones See Remarks | $16k 20,000 shares | +18% | |
| 64Notable | Corvus Pharmaceuticals, Inc. | Richard A Miller Md President and CEO | $45k 60,000 shares | +4% | |
| 66Notable | Corvus Pharmaceuticals, Inc. | Leiv Lea Chief Financial Officer | $26k 34,000 shares | +34% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.